Rockwell Medical shares surge 29.01% after-hours as preliminary Q4 results show 22% gross margin, cash flow positivity, and improved profitability.

Rockwell Medical surged 29.01% in after-hours trading following the release of preliminary Q4 2025 financial results and a renewed supply contract with a major U.S. dialysis provider. The company reported Q4 net sales of $18.6 million (exceeding estimates of $16.55 million), a 22% gross margin (up from 14% in Q3), and cash flow positivity of $2.3 million. Additionally, the extended multi-year supply agreement includes price increases through 2026, providing revenue visibility. CEO Mark Strobeck emphasized operational improvements, profitability strides, and a focus on growth and diversification in 2026. The dual catalysts—stronger-than-expected financials and contract renewal—positioned the company for long-term stability, driving the sharp post-announcement rally.